Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Daxor Corporation Common Stock

DXR

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $8.08 – $8.44
Volume 1,514
Market cap $49M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for DXR.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for DXR.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas through its turnkey ezBVA Lab send-out model. The service provides 98% accurate blood volume measurements within 24 hours without requiring capital equipment, enabling clinicians to optimize decongestion strategies and reduce hospital readmissions.

GlobeNewswire Inc.

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor Corporation will exhibit its FDA-cleared Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference (July 9-12, 2026) in Texas. The company emphasizes how BVA provides objective plasma and red blood cell data to improve dysautonomia therapy, representing a shift from subjective symptom tracking to precision, data-driven diagnostics.

GlobeNewswire Inc.

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor Corporation announced a definitive agreement to sell 765,958 shares of common stock at $11.75 per share to fundamental investors, raising approximately $9 million in gross proceeds. The offering is expected to close on January 26, 2026, with net proceeds intended for general corporate purposes and working capital. Lake Street Capital Markets is serving as the exclusive placement agent.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jan 5, 2018$0.03Jan 12, 2018recurring
Dec 20, 2016$0.03Dec 29, 2016recurring
Dec 18, 2015$0.04Dec 29, 2015recurring
Dec 4, 2014$0.03Dec 26, 2014recurring
Dec 5, 2013$0.05Dec 27, 2013recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.